PINE BROOK, N.J., Nov. 2, 2011 /PRNewswire/ -- Diopsys, Inc. announced today that its Visual Evoked Potential (VEP) Vision Testing Systems have been awarded the CE mark. The company has begun a roll-out of its patented vision testing devices to EU customers.
Diopsys completed a rigorous inspection of its total quality system in order to qualify for CE status. “Having the CE mark opens many opportunities for us to provide clinicians and patients across the EU access to our advanced VEP technology,” says Joseph Fontanetta, CEO of Diopsys, “Our VEP devices are designed to be used in an office setting and our patented technology overcomes many limitations of traditional VEP devices. Testing times are much faster than older VEP devices and our reports are easier to interpret. We are proud to bring an operator-friendly, objective, functional vision test to patients in need.”
Diopsys is the developer and marketer of the Diopsys® NOVA-VEP Vision Testing Systems utilized by ophthalmologists and optometrists to aid in the detection, diagnosis and treatment of vision disorders, including glaucoma, a disease affecting millions globally. The company has also developed and markets the Enfant® Pediatric VEP Vision Testing System, a device used to test for visual deficits, including amblyopia, in children as young as six months of age.
Visual Evoked Potentials (VEPs) are electrical signals that are a measure of the electrophysiological activity at the visual cortex. VEP results are a representation of the functional integrity of all levels of the visual pathway including the eye, retina, optic nerve, and visual cortex. This technology has been used for a variety of applications that involve neuro-visual disorders such as glaucoma, amblyopia, multiple sclerosis and diabetic retinopathy, among many others.(1,2,3,4 )
About Diopsys
Diopsys, Inc. (www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing Visual Evoked Potential (VEP) technology.
References
1. Prata TS, Lima VC, De Moraes CG, Trubnik V, Derr P, Liebmann JM, Ritch R, Tello C. Short Duration Transient Visual Evoked Potentials in Glaucomatous Eyes. J Glaucoma. 2011 May 10. [Epub ahead of print]
2. Simon J, Siegfried J, Mills M, Calhoun J, Gurland J. A New Visual Evoked Potential System for Vision Screening in Infants and Young Children. Journal of AAPOS. 8.6 (2004): 549-554.
3. Garcia-Martin E, Pueyo V, Ara JR, Almarcegui C, Martin J, Pablo L, Dolz I, Sancho E, Fernandez FJ. Effect of optic neuritis on progressive axonal damage in multiple sclerosis patients. Mult Scler. 2011 Jul;17(7):830-7. Epub 2011 Feb 7.
4. Parisi V, Uccioli L. Visual electrophysiological responses in persons with type 1 diabetes. Diabetes Metab Res Rev. 2001 Jan-Feb;17(1):12-8.
SOURCE Diopsys, Inc.
